DTB Podcast

For 50 years, Drug and Therapeutics Bulletin (DTB) has provided rigorous and independent evaluations of, and practical advice on, individual treatments and the overall management of disease for doctors, pharmacists and other healthcare professionals. DTB has always been wholly independent of the pharmaceutical industry, Government and regulatory authorities. DTB is also free of advertising and other forms of commercial sponsorship. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page - https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309.

Listen on:

  • Apple Podcasts
  • Podbean App
  • Spotify
  • Amazon Music
  • TuneIn + Alexa
  • iHeartRadio
  • PlayerFM
  • Listen Notes
  • Samsung
  • Podchaser
  • BoomPlay

Episodes

Wednesday Aug 30, 2023

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the September 2023 issue of DTB. They discuss concerns over redacted data in NICE appraisal documents (https://dtb.bmj.com/content/61/9/130). They review a placebo-controlled study that assessed the use of spironolactone for women with acne (https://dtb.bmj.com/content/61/9/132). The main article explores anticholinergic burden and the risk of cognitive decline, dementia and increased mortality associated with long-term use of drugs with anticholinergic activity (https://dtb.bmj.com/content/61/9/135).
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email dtb@bmj.com. Thank you for listening.

Wednesday Jul 26, 2023

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the August 2023 issue of DTB. They discuss measurement of fractional exhaled nitric oxide (FeNO) in the management of asthma (https://dtb.bmj.com/content/61/8/114). They review a study that assessed the use of H. pylori eradication in people taking low-dose aspirin (https://dtb.bmj.com/content/61/8/116). The main article explores the evidence for the use of finerenone for CKD associated with type 2 diabetes (https://dtb.bmj.com/content/61/8/120).
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email dtb@bmj.com. Thank you for listening.

Wednesday Jun 28, 2023

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the July 2023 issue of DTB. They discuss evidence-based medicine, access to evidence and increasing use of press releases and social media to present evidence (https://dtb.bmj.com/content/61/7/98). They talk about the safety of isotretinoin (https://dtb.bmj.com/content/61/7/99) and review a study that assessed the accuracy of conflict of interest statements in clinical guidelines (https://dtb.bmj.com/content/61/7/100). The main review article explores the evidence for cardiac and renal effects of SGLT2 inhibitors (https://dtb.bmj.com/content/61/7/103). They begin by discussing the impact of the shortage of Utrogestan.

Wednesday Jun 14, 2023

In a series of podcasts to mark the 60th anniversary of DTB, we talk to some of DTB's Editorial Board members and other colleagues about their work and their involvement with DTB. In this podcast, David Phizackerley (DTB deputy editor) talks to Barbara Mintzes (DTB associate editor)  who is Associate Professor at the School of Pharmacy and Charles Perkins Centre at the University of Sydney, where she has worked since 2015.  Her background is in epidemiology and the main focus of her work is on pharmaceutical policy, including the effects of direct-to-consumer advertising and physician-directed promotion on medicine use. Barbara talks about her interest in medicines policies, the impact of pharmaceutical and medical device company payments to clinicians, medicalisation of normal life, medicine safety scandals and the impact on those who have been harmed by medicines with a particular focus on women's health.
 
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email dtb@bmj.com. Thank you for listening.

Wednesday May 31, 2023

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the June 2023 issue of DTB. They discuss new guidelines on post-exposure prophylaxisfor varicella or shingles during pregnancy (https://dtb.bmj.com/content/61/6/82). They review the effect of low-dose aspirin on fractures and falls (https://dtb.bmj.com/content/61/6/85), and talk about a study that does not provide meaningful cardiovascular outcome data for inclisiran (https://dtb.bmj.com/content/61/6/86). The main review article explores hospitalisation as a consequence of medication-related harm and the need to reduce the burden of harm caused by medication (https://dtb.bmj.com/content/61/6/87). They begin by discussing an announcement from NHS England that antibiotics will be provided without the need for a prescription from community pharmacies to free up GP time.
The contact address for the DTB team is dtb@bmj.com.Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

Thursday Apr 20, 2023

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the May 2023 issue of DTB. They celebrate 60 years since DTB became independent from The Medical Letter and discuss what DTB stands for (https://dtb.bmj.com/content/61/5/66). They review a retrospective cohort study involving people taking oral anticoagulants that compared the risk of bleeding and embolic events in new users of NSAIDs with those not prescribed NSAIDs (https://dtb.bmj.com/content/61/5/67). They also talk about the main review article that explores the therapeutics of siRNA medicines (https://dtb.bmj.com/content/61/5/72). They begin by discussing the UK Government’s recent Budget statement that the MHRA will introduce a new approval process for medicines that have been licensed elsewhere.

Wednesday Mar 22, 2023

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the April 2023 issue of DTB. They discuss evidence around morning and evening doses of antihypertensive medication (https://dtb.bmj.com/content/61/4/50). They review a study that analysed health technology assessment decisions made in Australia, Canada and England (https://dtb.bmj.com/content/61/4/51) and also talk about managing skin conditions in women who are planning pregnancy or who are pregnant (https://dtb.bmj.com/content/61/4/55). They begin by responding to a listener's letter about last month's podcast.
The Prescribing for pregnancy series of articles can be found here: https://dtb.bmj.com/pages/prescribing-for-pregnancy-series/

Wednesday Mar 08, 2023

In a series of podcasts to mark the 60th anniversary of DTB, we talk to some of DTB's Editorial Board members and other colleagues about their work and their involvement with DTB. In this podcast, recorded May 2022, David Phizackerley (DTB's deputy editor) talks to Joanna Girling who is a consultant in obstetric medicine in north London and has been involved with DTB since 2006. Joanna talks about her clinical work, her role with establishing the local maternity network and her involvement in research. She also talks about supporting women who have pre-existing medical conditions and who are pregnant or who are planning pregnancy and the importance of checking that they are on the most appropriate medicines.
The contact address for the DTB team is dtb@bmj.com.
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listenin

Monday Feb 20, 2023

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the March 2023 issue of DTB. They discuss incorrect penicillin allergy labels and ways that these can be corrected (https://dtb.bmj.com/content/61/3/34). They review clinical trial results for lecanameb in early Alzheimer's disease (https://dtb.bmj.com/content/61/3/37) and also talk about a new combined oral contraceptive that contains estetrol and drospirenone (https://dtb.bmj.com/content/61/3/39). They begin by discussing a proposal from the National Institute for Health and Care Excellence to lower the threshold for offering statins for primary prevention.
The contact address for the DTB team is dtb@bmj.com.
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

Monday Jan 23, 2023

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the February 2023 issue of DTB. They discuss concerns over a national initiative in England to transfer people with atrial fibrillation to edoxaban from other DOACs (https://dtb.bmj.com/content/61/2/18). They review a study that examined whether the correct dose of DOAC was used in people with renal impairment (https://dtb.bmj.com/content/61/2/21). They talk about the use of empagliflozin in people with heart failure (https://dtb.bmj.com/content/61/2/22) and finish with an overview of an article that discusses prescribing for pregnancy for those with inflammatory rheumatic disease (https://dtb.bmj.com/content/61/2/24).
60th anniversary interview with Dr John Dowden: https://soundcloud.com/bmjpodcasts/dtb-60th-anniversary-podcast-interview-john-dowden
Trends in direct oral anticoagulant (DOAC) prescribing in English primary care (2014–2019): https://heart.bmj.com/content/109/3/195
The contact address for the DTB team is dtb@bmj.com.
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

* The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.

Copyright 2023 All rights reserved.

Version: 20240320